Multiparametric SCores for Prediction of Myocardial FIbrosis in Patients with MITral VAlve PRolapse

Launched by CENTRO CARDIOLOGICO MONZINO · Mar 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying patients with a condition called Mitral Valve Prolapse (MVP), where one or both mitral valve leaflets do not close properly. The main goal is to develop a scoring system that can help predict heart tissue damage (known as fibrosis) using a type of imaging called Cardiac Magnetic Resonance (CMR). Researchers also want to understand which specific features of MVP might increase the risk of serious heart issues, like abnormal heart rhythms or sudden cardiac death.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed diagnosis of MVP based on an echocardiogram, which is a test that uses sound waves to create images of the heart. Those who have other serious heart conditions or issues that make it difficult to perform the imaging will not be included. If you join the study, you can expect to undergo various assessments and tests to help the researchers gather important information about MVP and its effects on heart health. This trial is currently recruiting participants of all genders, and your involvement could contribute to better understanding and management of MVP.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age ≥ 18 years
• • Echocardiographic diagnosis of mitral valve prolaspe, defined as a systolic displacement of one or both mitral leaflets ≥ 2 mm above the plane of the mitral valve annulus in long-axis views
• Exclusion Criteria:
• • age\< 18 years
• • coexistence of other cardiomyopathies or other ≥ moderate valve diseases
• • scarce acoustic transthoracic echocardiographic window
• • usual contraindications for cardiac magnetic resonance